Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients

计划入组 9 人 · 首次发布于 2008 年 9 月 23 日

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

计划入组 57 人 · 首次发布于 2022 年 8 月 24 日

Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments

计划入组 650 人 · 首次发布于 2024 年 6 月 7 日

GSK-2302032A

EGFR inhibitors (non-small cell lung cancer)

GFPT2 inhibitors (non-small-cell lung cancer)

ADDARIO LUNG CANCER MEDICAL INSTITUTE

United States

European Lung Cancer Working Party

Belgium

Summit Therapeutics Inc.

United States

Enhertu Nears EU Approval for HER2-Positive Breast Cancer Treatment

T-DXd-Pembrolizumab Combination Shows Promise in HER2-Positive NSCLC with 80% Response Rate in First-Line Setting

Guardant Health Partners with Nuvalent in Multi-Year Collaboration for Precision Cancer Diagnostics